Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis

被引:157
作者
Hu, YM
Coates, ARM
Mitchison, DA
机构
[1] St George Hosp, Sch Med, Dept Med Microbiol, London SW17 0RE, England
[2] Biotherapies Ltd, Stockport, Lancs, England
关键词
D O I
10.1128/AAC.47.2.653-657.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The bactericidal activities of ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, and gatifloxacin were tested in three models of rifampin-tolerant Mycobacterium tuberculosis persisters. Model 1 was a 100-day-old, unshaken, anaerobically adapted culture in which serial dilutions of the quinolones were incubated for 5 days and CFU counts were then done In models 2 and 3, 100 mg of rifampin/liter was added to the 100-day culture for 5 or 7 days to produce tolerant organisms that did not grow on plates; the rifampin was then washed off, fresh medium was added to allow recovery of growth on plates, and the culture was incubated for 7 days before CFU counts. In model 2, the quinolones were added after rifampin had been washed off, whereas in model 3 the quinolones were added to the cultures containing rifampin. In models I and 2, ciprofloxacin had the least bactericidal activity, ofloxacin and levotfloxacin had greater activities, and moxifloxacin and gatifloxacin had the greatest activities. In model 3, ofloxacin had no detectable activity whereas moxifloxacin killed about log(10) 0.279 CFU of the persisters per ml at concentrations attainable in lesions; isoniazid had virtually no activity. These findings predict that ofloxacin will not be found to have effective sterilizing activity in clinical studies now planned whereas moxifloxacin will be able to shorten treatment.
引用
收藏
页码:653 / 657
页数:5
相关论文
共 16 条
[1]   In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis [J].
Alvirez-Freites, EJ ;
Carter, JL ;
Cynamon, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) :1022-1025
[2]   Foreword from the co-editor-in-chief [J].
Brennan, PJ .
TUBERCULOSIS, 2001, 81 (1-2) :1-1
[3]   The future challenges facing the development of new antimicrobial drugs [J].
Coates, A ;
Hu, YM ;
Bax, R ;
Page, C .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (11) :895-910
[4]   Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide [J].
Hu, YM ;
Mangan, JA ;
Dhillon, J ;
Sole, KM ;
Mitchison, DA ;
Butcher, PD ;
Coates, ARM .
JOURNAL OF BACTERIOLOGY, 2000, 182 (22) :6358-6365
[5]   Increased levels of sigJ mRNA in late stationary phase cultures of Mycobacterium tuberculosis detected by DNA array hybridisation [J].
Hu, YM ;
Coates, ARM .
FEMS MICROBIOLOGY LETTERS, 2001, 202 (01) :59-65
[6]   In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis [J].
Ji, BH ;
Lounis, N ;
Maslo, C ;
Truffot-Pernot, C ;
Bonnafous, P ;
Grosset, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :2066-2069
[7]  
JINDANI A, 1980, AM REV RESPIR DIS, V121, P939
[8]   POWERFUL BACTERICIDAL ACTIVITY OF SPARFLOXACIN (AT-4140) AGAINST MYCOBACTERIUM-TUBERCULOSIS IN MICE [J].
LALANDE, V ;
TRUFFOTPERNOT, C ;
PACCALYMOULIN, A ;
GROSSET, J ;
JI, BH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (03) :407-413
[9]   Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice [J].
Lounis, N ;
Bentoucha, A ;
Truffot-Pernot, C ;
Ji, BH ;
O'Brien, RJ ;
Vernon, A ;
Roscigno, G ;
Grosset, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (12) :3482-3486
[10]  
Mitchison DA, 2000, INT J TUBERC LUNG D, V4, P796